NIOX Group Plc

CIR

GB00BJVD3B28

Pharmaceuticals

Market Closed - London S.E. Other stock markets 11:35:19 2024-04-19 am EDT			5-day change	1st Jan Change
64.6 ^GBX	0.00%		-1.37%	-3.58%

Apr. 04	NIOX Group Plc Proposes Final Dividend for the Financial Year Ended 31 December 2023, Payable on 24 June 2024	CI
Mar. 26	EARNINGS: CAB Payments profit drops, Life Science REIT cuts dividend	AN

Circassia Pharmaceuticals : Notice of Interim Results

August 24, 2017 at 11:14 am EDT

24 August 2017

Circassia Pharmaceuticals PLC

Notice of Interim Results

Circassia Pharmaceuticals plc (LSE: CIR) will announce its interim results for the six months ended 30 June 2017on Wednesday 27 September 2017.

Following the results announcement, the company will hold an analyst meeting at 9.30am at the offices of FTI Consulting, 200 Aldersgate, Aldersgate Street, London, EC1A 4HD. A webcast of the presentation will be available on the Company's website (www.circassia.com).

For further information please contact:

FTI Consulting
Mo Noonan / Carissa Gilbert	+44 (0) 20 3727 1000

Circassia Pharmaceuticals plc published this content on 24 August 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 24 August 2017 15:12:01 UTC.

Original documenthttp://otp.investis.com/clients/uk/circassia/rns/regulatory-story.aspx?cid=797&newsid=911411

Public permalinkhttp://www.publicnow.com/view/650F5B34A5B411C89407FDF73753D450FA3FBA3E

Latest news about NIOX Group Plc

NIOX Group Plc Proposes Final Dividend for the Financial Year Ended 31 December 2023, Payable on 24 June 2024	Apr. 04	CI
EARNINGS: CAB Payments profit drops, Life Science REIT cuts dividend	Mar. 26	AN
Earnings Flash (NIOX.L) NIOX GROUP Reports FY23 Revenue GBP36.8M	Mar. 26	MT
Earnings Flash (NIOX.L) NIOX GROUP Posts FY23 EPS GBX2.38	Mar. 26	MT
NIOX Group Plc Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 26	CI
ZEPHYRx and NIOX Announce to Work Together to Advance Respiratory Clinical Research	Feb. 08	CI
XP Factory revenue doubles; Zotefoams trades in line	Jan. 18	AN
EARNINGS: Andrews Sykes revenue up; Safestay optimistic	23-09-26	AN
NIOX Group Plc Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-26	CI
FTSE Closes Tuesday Up 0.6% Lifted by Banks, Oil Stocks; Ocado Soars	23-07-18	DJ
UK Consumers Cut Spending Amid Rising Mortgage Rates	23-07-18	DJ
AIM WINNERS & LOSERS: Pelatro reports customer payment delays	23-07-18	AN
NIOX shares up as rising half-year revenue driven by Clinical results	23-07-18	AN
NIOX Group Plc Announces Special Dividend, Payable on 15 September 2023	23-07-18	CI
FTSE 100 Closes Slightly Down as Property Stocks Slip on House-Prices Data	23-06-07	DJ
NIOX declares special dividend and says more payouts to come	23-06-07	AN
UK Inflation to Be Among Highest in Major Economies in 2023, OECD Says	23-06-07	DJ
NIOX Group Plc Announces Special Dividend, Payable on 15 September 2023	23-06-07	CI
TheWorks.co.uk reports "resilient" annual performance	23-05-18	AN
Niox swings to profit in 2022; ScS loss balloons	23-03-21	AN
Earnings Flash (NIOX.L) NIOX GROUP Reports FY22 Revenue GBP31.3M	23-03-21	MT
Earnings Flash (NIOX.L) NIOX GROUP Posts FY22 EPS GBX3.19	23-03-21	MT
NIOX Group Plc Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-21	CI
NIOX Group Plc Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-21	CI
FTSE 100 Closes Down 0.1% Amid AstraZeneca, Unilever Weakness	23-01-17	DJ

Chart NIOX Group Plc

Duration

Period

More charts

Company Profile

NIOX Group plc is a United Kingdom-based diagnostics and management company that is focused on asthma. The Company's product NIOX uses patented technology to measure fractional exhaled nitric oxide (FeNO). Its NIOX FeNO measurement and monitoring products are used by physicians around the globe to help improve asthma diagnosis and management. The Company offers NIOX VERO, a point of care device for the accurate measurement of nitric oxide (NO) as a biomarker of airway inflammation to help diagnose and manage asthma. The device is used by healthcare professionals to improve asthma care, which assists diagnosis, determining responsiveness to inhaled corticosteroids, tailoring inhaled steroid use, monitoring treatment compliance, and reducing the likelihood of exacerbations in at-risk patients compared to traditional monitoring. The Company offers products and services in around 50 countries.

Sector

Pharmaceuticals

Calendar

2024-05-21 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for NIOX Group Plc

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.646 GBP

Average target price

0.76 GBP

Spread / Average Target

+17.65%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
NIOX GROUP PLC	-3.58%	341M
ELI LILLY AND COMPANY	+24.60%	672B
NOVO NORDISK A/S	+24.08%	550B
JOHNSON & JOHNSON	-5.63%	351B
MERCK & CO., INC.	+15.37%	317B
ABBVIE INC.	+7.38%	292B
ASTRAZENECA PLC	+3.26%	211B
NOVARTIS AG	+0.78%	203B
PFIZER, INC.	-9.69%	144B
AMGEN INC.	-6.63%	141B

Other Pharmaceuticals

NIOX Group Plc

Equities

CIR

GB00BJVD3B28

Pharmaceuticals

Circassia Pharmaceuticals : Notice of Interim Results

Latest news about NIOX Group Plc

Chart NIOX Group Plc

Company Profile

Income Statement Evolution

Ratings for NIOX Group Plc

Analysts' Consensus

EPS Revisions

Annual profits - Rate of surprise

Sector Other Pharmaceuticals